Online inquiry

IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7865MR)

This product GTTS-WQ7865MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APCS gene. The antibody can be applied in AL amyloidosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001639.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 325
UniProt ID P02743
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7865MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12260MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ2069MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ14111MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ4427MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ10883MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ9857MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ14044MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ14012MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW